StockMarketWire.com - Biopharmaceutical company PureTech Health has announced that its affiliate Gelesis has received a $10.6m grant to support the commercial manufacturing of its first product, Plenity.

The company said it hoped to launch Plenity in the United States in the second half of 2019, with broader US availability by prescription in 2020. As such, it expected to see "significant growth" of its headcount.

The grant was provided by the Puglia region in Italy, where Gelesis' current material science research and development and clinical supply manufacturing is located.

Plenity has been cleared by the FDA as a weight management aid for adults with a body mass index of 25-40kg/m2, when used in conjunction with diet and exercise.




At 9:31am: [LON:PRTC] PureTech Health Plc share price was -2p at 186p



Story provided by StockMarketWire.com